PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
Advanced well differentiated neuroendocrine tumors (NET) have poor sensitivity to chemotherapy. Biotherapy and targeted therapy are the main treatment options for these patients. Approaches to the 2nd and subsequent lines of treatment have not been developed to date. VEGFR blocker bevacizumab is act...
Main Authors: | G. S. Emelianova, N. F. Orel, V. A. Gorbunova, A. A. Kolomeytseva, A. A. Kuznetsova, A. E. Kuzminov, A. A. Fedenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2017-12-01
|
Series: | Сибирский онкологический журнал |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/647 |
Similar Items
-
NEUROENDOCRINE TUMORS OF THE CERVIX
by: K. V. Safronova, et al.
Published: (2020-10-01) -
Clinical and morphological characteristics of ovarian neuroendocrine tumors
by: S. O. Nikogosyan, et al.
Published: (2019-07-01) -
Octreotide in the treatment of neuroendocrine carcinomas: Is the success achieved?
by: L. Yu. Morgunov
Published: (2015-06-01) -
Biochemical factors in the blood serum of neuroendocrine tumor patients with carcinoid syndrome
by: N. V. Lyubimova, et al.
Published: (2022-12-01) -
BRCA1GENE EXPRESSION IN ENDOCRINE TUMORS OF THE GASTROINTESTINAL TRACT
by: I. G. Gafton, et al.
Published: (2016-02-01)